Dasatininb

Manufactured by Selleck Chemicals

Dasatinib is a tyrosine kinase inhibitor that is used in the treatment of certain types of cancer, including chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It functions by inhibiting the activity of several tyrosine kinases, including BCR-ABL, SRC, and c-KIT, which are involved in the growth and proliferation of cancer cells.

Automatically generated - may contain errors

Lab products found in correlation

Amastatin, by Enzo Life Sciences (1 mentions) Pepstatin, by Merck Group (1 mentions) Chloroquine, by Merck Group (1 mentions) Concanamycin a, by Santa Cruz Biotechnology (1 mentions) Gm6001, by Enzo Life Sciences (1 mentions) Aprotinin, by Merck Group (1 mentions) Leupeptin, by Merck Group (1 mentions) Everolimus, by Santa Cruz Biotechnology (1 mentions) Methyl thiazolyl tetrazolium (mtt), by Merck Group (1 mentions) Dimethyl sulfoxide (dmso), by Merck Group (1 mentions) Mk2206, by Axon Medchem (1 mentions) Azd8055, by Axon Medchem (1 mentions) Imark microplate absorbance reader, by Bio-Rad (1 mentions) Gdc 0941, by Axon Medchem (1 mentions) Cisplatin, by Accord Healthcare (1 mentions)

2 protocols using dasatininb

Storage of Protease Inhibitors

Check if the same lab product or an alternative is used in the 5 most similar protocols

Leupeptin and Aprotinin (Sigma) were reconstituted in aqueous solution and stored at -20°C. Pepstatin, Chloroquine (Sigma), Amastatin, GM6001 (Enzo Life Sciences), Dasatininb (Selleck Chemicals), Concanamycin A (Santa Cruz Biotechnology) and Cytochalasin B (ChemCruz) were reconstituted in DMSO and stored at -20°C.

Alari-Pahissa E., Ataya M., Moraitis I., Campos-Ruiz M., Altadill M., Muntasell A., Moles A, & López-Botet M. (2021). NK cells eliminate Epstein-Barr virus bound to B cells through a specific antibody-mediated uptake. PLoS Pathogens, 17(8), e1009868.

+ Open protocol

+ Expand

Cytotoxicity Assay for Cancer Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols

Cells were plated in 96-well plates at a density of 5,000 cells/well for Tera, TeraCP, and 833KE, and 7,000 cells/well for Scha and NCCIT. At 2 to 3 hours after plating cells, one of the following agents was added, cisplatin (Accord Healthcare), Everolimus (Santa Cruz Biotechnology), GDC-0941, MK-2206, AZD8055, MLN0128 (also known as TAK-228; all from Axon Medchem), and dasatininb (Selleckchem). After a 96-hour incubation, 3-(4,5-dimethylthiazol-2-yl)-2, 5 diphenyltetrazolium (MTT; Sigma) was added at a concentration of 5 mg/mL for 4 hours. Medium was removed and the formazan crystals were dissolved in DMSO (Sigma). Absorbance was measured at 520 nm using an iMARK microplate absorbance reader (Bio-Rad). Relative survival was determined as the decrease in signal compared with untreated cells.

Rosas-Plaza X., de Vries G., Meersma G.J., Suurmeijer A.J.H., Gietema J.A., van Vugt M.A.T.M, & de Jong S. (2020). Dual mTORC1/2 Inhibition Sensitizes Testicular Cancer Models to Cisplatin Treatment. Molecular cancer therapeutics, 19(2).

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!